Budesonide as maintenance treatment in Crohn's disease: a placebo‐controlled trial
Authors:
- 14 February 2005
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 21 (4) , 363-371
Abstract
Summary: Aim : To assess the efficacy and safety of budesonide capsules 6 mg daily for prolongation of time to relapse and maintenance of remission in patients with Crohn's disease (CD) affecting the ileum and/or ascending colon.Methods : In a double‐blind, placebo‐controlled, multicentre trial, 110 patients with CD, who had previously achieved remission in a placebo‐controlled trial of budesonide 9 mg daily, were randomly assigned to receive budesonide 6 mg once daily or placebo for 52 weeks. Primary outcome measure was time to relapse [CD activity index (CDAI) of >150 plus an increase of at least 60 points from study entry or withdrawal due to clinical deterioration].Results : Median time to relapse was 360 days for budesonide patients; 169 days for placebo patients (P = 0.132). No significant differences were seen between groups in relapse rates at 1 year. Budesonide was safe and well tolerated, with a similar adverse events profile to placebo.Conclusion : Patients treated with budesonide 6 mg once daily had a trend towards a prolonged time to relapse and lower CDAI scores compared with patients treated with placebo, but relapse rates were not significantly different at the 1‐year end point.Keywords
This publication has 26 references indexed in Scilit:
- A pharmacoscintigraphic evaluation of oral budesonide given as controlled‐release (Entocort) capsulesAlimentary Pharmacology & Therapeutics, 2003
- Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsulesEuropean Journal of Gastroenterology & Hepatology, 2002
- Inflammatory Bowel DiseaseNew England Journal of Medicine, 2002
- A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's diseaseGastroenterology, 2000
- Controlled trial of oral 5‐aminosalicylic acid for the prevention of early relapse in Crohn's diseaseAlimentary Pharmacology & Therapeutics, 1997
- Oral budesonide is as effective as oral prednisolone in active Crohn’s diseaseGut, 1997
- Mesalamine in Crohn's disease with steroid-induced remission: Effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires DigestivesGastroenterology, 1996
- A controlled double blind study of azathioprine in the management of Crohn's disease.Gut, 1995
- Oral Budesonide for Active Crohn's DiseaseNew England Journal of Medicine, 1994
- Overview of Newer Glucocorticosteroid Preparations for Inflammatory Bowel DiseaseCanadian Journal of Gastroenterology and Hepatology, 1990